While recombinant TRAIL variants, as well as agonist Ab with specificity for the TRAIL receptors DR4 and DR5, were used for inhibiting the growth of various types of malignant cells both in vitro and in vivo [26–29], others, found the same HCC cell lines under study here, (SK-HEP-1, HepG2 and Huh7), to be highly resistant to TRAIL-induced apoptosis [30,31]. Here, TNFRSF10B is linked to hepatocellular carcinoma.